Gilead Sciences (GILD) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $2.55
- Estimate
- $2.19
- Surprise
- +16.2%
- Revenue (period 2026-09-30)
- $8.30B
- Score at report (before → after)
- 5.3 → 5.4/10
Revenue source: xbrl.
How the report landed
Gilead Sciences (GILD) beat the $2.19 estimate with adjusted EPS of $2.55 — a large 16.2% upside surprise. TrendMatrix's engine moved from Sell (5.3/10) to Hold at 5.4/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates GILD Sell at 4.4/10.
4 of the last 4 quarters beat the estimate; this quarter's +16.2% surprise compares with a +8.0% four-quarter average. Next scheduled report: 2027-02-09.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (4/4)
What argues against it
- Concentration risk — Customer: three large wholesalers (Cardinal Health, Cencora, McKesson) (90.0%)
- Analyst target reached - limited upside remaining
- Leverage penalty (D/E 2.0): -1.5
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $166.53
- Stop
- $156.85
Model outputs from TrendMatrix’s engine as of 2026-11-19 — shown for context, not personalized investment advice.
GILD at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - General
- Market cap
- $209.59B
- P/E (fwd)
- 16.6
- 52-week range
- $116.88–$176.58
- Off 52-week high
- 5.7%
- RSI (14)
- 43
- Volume vs avg
- 0.78×
- Score today
- 4.4/10